Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 9:56 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,614 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Coronary Occlusion Clear all

Conditions: Healthy Volunteers
Interventions: Placebo, MEDI5884 Dose 1, MEDI5884 Dose 2, MEDI5884 Dose 3, MEDI5884 Dose 4; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Glendale, California

Conditions: Coronary Artery Disease
Interventions: iodixanol; Drug
Lead sponsor: GE Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Coronary Artery Disease, Angina Pectoris
Interventions: Decision-making tool for coronary artery disease treatment; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Primary Prevention of Atherosclerotic Cardiovascular Disease
Interventions: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, Placebo in 1.5ml; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years to 79 Years
Enrollment: 14,012 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 241
States / cities: Birmingham, Alabama • Fairhope, Alabama • Foley, Alabama + 187 more

Conditions: Coronary Artery Disease
Interventions: Not listed
Lead sponsor: Rebecca Torguson; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Coronary Artery Disease, Acute Coronary Syndrome
Interventions: Fractional Flow Reserve; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 2,217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 4
States / cities: Huntsville, Alabama • Orlando, Florida • Decatur, Georgia + 1 more

Conditions: Aortic Valve Disease, Aortic Stenosis
Interventions: Perceval valve, other stented biological valve; Device
Lead sponsor: Corcym S.r.l; Industry
Eligibility: 18 Years and older
Enrollment: 914 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 5
States / cities: Indianapolis, Indiana • Portland, Maine • Cleveland, Ohio + 2 more

Conditions: Right Bundle-Branch Block, Heart Failure, His-bundle Pacing, Cardiac Resynchronization Therapy
Interventions: His-CRT implantation, BIV-CRT implantation; Procedure
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 14
States / cities: Phoenix, Arizona • Los Angeles, California • Tampa, Florida + 8 more

Conditions: Atrial Fibrillation (AF)
Interventions: Remapping Procedure; Device
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Bay Shore, New York

Conditions: Acute Renal Failure, Kidney Disease, Coronary Artery Disease
Interventions: IV isotonic saline, IV isotonic bicarbonate, N-acetylcysteine, Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 5,177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 35
States / cities: Tucson, Arizona • Little Rock, Arkansas • Palo Alto, California + 32 more

Conditions: Coronary Artery Disease
Interventions: Emerge™ 1.20 mm PTCA Dilatation Catheter; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Myocardial Infarction, Stable Angina, Coronary Artery Disease
Interventions: Early appointment (within 10 days), Routine referral (at 5 weeks); Behavioral · Other
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Breast Cancer Risk, Cardiovascular Disease Risk, Cardiometabolic Risk, Diabetes
Interventions: Breast Cancer, Cardiometabolic, Cardiovascular Risk Screening and Follow up; Behavioral
Lead sponsor: Precision Health Equity Initiative; Other
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 10,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2035
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Coronary Stenosis, Coronary Artery Disease
Interventions: IoNIR Ridaforolimus-Eluting Coronary Stent System; Device
Lead sponsor: Medinol Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Roslyn, New York

Conditions: Coronary Artery Disease
Interventions: Cleerly Labs and Cleerly ISCHEMIA; Device
Lead sponsor: Cleerly, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 21
States / cities: Mobile, Alabama • Huntington Park, California • San Diego, California + 18 more

Conditions: Severe Symptomatic Calcified Native Aortic Valve Stenosis
Interventions: Cerebral Protection System-The SENTINEL System with TAVR, TAVR; Device
Lead sponsor: Claret Medical; Industry
Eligibility: 18 Years and older
Enrollment: 363 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 14
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Clearwater, Florida + 9 more

Conditions: Peripheral Arterial Disease
Interventions: Ischemic preconditioning, Control; Other
Lead sponsor: Center for Veterans Research and Education; Other
Eligibility: 18 Years and older
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Coronary Artery Disease
Interventions: SYNERGY 48 mm; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 8
States / cities: Birmingham, Alabama • Saint Paul, Minnesota • New York, New York + 5 more

Conditions: Williams Syndrome, Supravalvular Aortic Stenosis, Cardiovascular Disease
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 1 Day to 85 Years
Enrollment: 305 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 3
States / cities: Bethesda, Maryland • St Louis, Missouri • Columbus, Ohio

Conditions: Atrial Fibrillation, Coronary Artery Disease
Interventions: Regadenoson MRI, Gadobenate dimeglumine; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 100 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Atherosclerosis, Cardiovascular Diseases, Lipoprotein(a)
Interventions: Lepodisiran, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 45 Years to 80 Years
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 17
States / cities: La Jolla, California • Northridge, California • Torrance, California + 14 more

Conditions: Coronary Artery Disease, High-risk Percutaneous Coronary Intervention, Interventional Cardiology
Interventions: Supira System; Device
Lead sponsor: Supira Medical; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 4
States / cities: Sacramento, California • Atlanta, Georgia • New York, New York + 1 more

Conditions: Atherosclerosis, Heart Failure, Congestive, Hypertension, Myocardial Infarction
Interventions: Angiotensin II type 1 receptor antagonists; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Atherosclerosis, Coronary Artery Disease
Interventions: OMEGA™ Monorail Coronary Stent System; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 328 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 22
States / cities: Hot Springs, Arkansas • Little Rock, Arkansas • Loma Linda, California + 18 more

Search by objective public record fields.

Phase 1, Single Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of MEDI5884

Safety and Effectiveness of Visipaque 320mg-I/ml for Use in Contrast-Enhanced CT Angiography of Arteries of the Heart

Patient-Reported Preferences Affecting Revascularization Decisions

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Registry Experience at the Washington Hospital Center, DES - Endeavor for Myocardial Infarction

PRESSUREwire Study

Perceval Sutureless Implant Versus Standard-Aortic Valve Replacement

His-Bundle Corrective Pacing in Heart Failure

Prospective Remapping With Concomitant Left Atrial Appendage Occlusion to Ensure Durable Electroporation Study

Prevention of Serious Adverse Events Following Angiography

Evaluation of Coronary Luminal Diameter Enlargement With Emerge™ 1.20 mm PTCA Dilatation Catheter

Readiness for Behavior Change After a Heart Attack

The RISC Registry--Risk Informed Screening Registry

IonMAN II Trial- Early Feasibility Study of the IoNIR Ridaforolimus-Eluting Coronary Stent System

A Randomized Comparison of Personalized Therapy Mgmt Based On Coronary Atherosclerotic Plaque Vs. Usual Care for Symptomatic Patients With Suspicion of CAD

Cerebral Protection in Transcatheter Aortic Valve Replacement

Cardiac Remote Ischemic Preconditioning Before Elective Major Vascular Surgery

A Clinical Trial to Assess the SYNERGY 48 mm Stent System for the Treatment of Atherosclerotic Lesion(s)

Williams Syndrome (WS) and Supravalvar Aortic Stenosis (SVAS) DNA and Tissue Bank

Regadenoson Stress-MRI to Identify Coronary Artery Disease in Atrial Fibrillation Patients

A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk

Early Feasibility Study of the Supira System in Patients Undergoing HRPCI

The Role of Angiotensin Type I Receptor in the Regulation of Human Coronary Vascular Function

The OMEGA Clinical Trial